Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes

INTRODUCTION: Erythropoiesis stimulating agents (ESAs) represents the principal treatments for anemia in patients with lower-risk myelodysplastic syndromes (MDS). Pre-treatment erythropoietin (EPO) level and previous blood transfusion requirement are the two major predictors for response to ESAs. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattakitpanitchakul, Saroj, Kobbuaklee, Sirorat, Wudhikarn, Kitsada, Polprasert, Chantana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080375/
https://www.ncbi.nlm.nih.gov/pubmed/34967586
http://dx.doi.org/10.31557/APJCP.2021.22.12.4037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080375/
https://www.ncbi.nlm.nih.gov/pubmed/34967586
http://dx.doi.org/10.31557/APJCP.2021.22.12.4037

Ejemplares similares